# Precigen, Inc.: overview PGEN · Nasdaq · CIK 1356090 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pgen.md) · [Financials](/companies/pgen/financials.md) · [Filings](/companies/pgen/filings.md) · [Insiders](/companies/pgen/insiders.md) Latest reported revenue: [$55.0m](/filings/0001356090-26-000030.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001356090-26-000030). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [1.3](/filings/0001356090-26-000017.md) | [0.9](/filings/0001356090-26-000030.md) | not reported | not reported | [23.3](/filings/0001356090-26-000017.md) | [55.0](/filings/0001356090-26-000030.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(1685.0%)](/filings/0001356090-26-000017.md) | [(3710.7%)](/filings/0001356090-26-000030.md) | not reported | not reported | [(25.8%)](/filings/0001356090-26-000017.md) | [41.2%](/filings/0001356090-26-000030.md) | | Net margin | % | not reported | not reported | [(4038.3%)](/filings/0001356090-26-000017.md) | [(3112.4%)](/filings/0001356090-26-000030.md) | not reported | not reported | [(34.1%)](/filings/0001356090-26-000017.md) | [36.5%](/filings/0001356090-26-000030.md) | | Diluted EPS | $ per share | [(0.09)](/filings/0001356090-25-000034.md) | not reported | [(0.18)](/filings/0001356090-26-000017.md) | [(0.09)](/filings/0001356090-26-000030.md) | [(1.06)](/filings/0001356090-25-000034.md) | not reported | [(0.02)](/filings/0001356090-26-000017.md) | [0.05](/filings/0001356090-26-000030.md) | | Free cash flow | $m | [(23.6) d](/filings/0001356090-25-000034.md) | [(9.3) d](/filings/0001356090-26-000009.md) | [(16.9)](/filings/0001356090-26-000017.md) | [(19.9) d](/filings/0001356090-26-000030.md) | [(29.5) d](/filings/0001356090-25-000034.md) | [(23.5) d](/filings/0001356090-26-000009.md) | [(44.1)](/filings/0001356090-26-000017.md) | [(18.2) d](/filings/0001356090-26-000030.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [14.3](/filings/0001356090-23-000004.md) | [26.9](/filings/0001356090-23-000004.md) | [6.2](/filings/0001356090-26-000009.md) | [3.9](/filings/0001356090-26-000009.md) | [9.7](/filings/0001356090-26-000009.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(1602.5%)](/filings/0001356090-26-000009.md) | [(3440.2%)](/filings/0001356090-26-000009.md) | [(1141.1%)](/filings/0001356090-26-000009.md) | | Net margin | % | [(646.0%)](/filings/0001356090-24-000007.md) | [105.2%](/filings/0001356090-25-000007.md) | [(1540.6%)](/filings/0001356090-26-000009.md) | [(3216.2%)](/filings/0001356090-26-000009.md) | [(2588.2%)](/filings/0001356090-26-000009.md) | | Diluted EPS | $ per share | [(0.47)](/filings/0001356090-24-000007.md) | [0.14](/filings/0001356090-25-000007.md) | [(0.39)](/filings/0001356090-26-000009.md) | [(0.47)](/filings/0001356090-26-000009.md) | [(1.37)](/filings/0001356090-26-000009.md) | | Free cash flow | $m | [(63.0)](/filings/0001356090-24-000007.md) | [(70.0)](/filings/0001356090-25-000007.md) | [(68.5)](/filings/0001356090-26-000009.md) | [(76.8)](/filings/0001356090-26-000009.md) | [(89.8)](/filings/0001356090-26-000009.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pgen/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Patient Capital Management, LLC](/funds/1854794.md) | 2026-06-30 | $108.5m | 19,036,976 | | Added +1,219,589 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $97.7m | 17,146,921 | | Added +1,923,730 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $68.4m | 12,002,465 | | Added +1,112,341 | | [Diametric Capital, LP](/funds/1719087.md) | 2026-06-30 | $52.8m | 9,269,926 | | Added +2,468,138 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $45.1m | 7,906,160 | | Added +757,164 | | [TANG CAPITAL MANAGEMENT LLC](/funds/1232621.md) | 2026-06-30 | $36.6m | 6,417,500 | | Unchanged | | [Boxer Capital Management, LLC](/funds/2018299.md) | 2026-06-30 | $29.4m | 5,150,000 | | Added +1,650,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $28.6m | 5,019,028 | | Added +405,599 | | [IRIDIAN ASSET MANAGEMENT LLC/CT](/funds/1033427.md) | 2026-06-30 | $23.0m | 4,031,963 | | Added +439,233 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $19.8m | 3,469,628 | | Added +1,055,306 | ## Recent filings [All 1,261 filings](/companies/pgen/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-04 | 16:08 ET | [10-Q](/filings/0001356090-26-000030.md) | Quarterly report, period 2026-06-30 | 0001356090-26-000030 | | 2026-08-04 | 16:05 ET | [8-K](/filings/0000950103-26-011876.md) | 2.02 Results of operations | 0000950103-26-011876 | | 2026-06-24 | 16:07 ET | [8-K](/filings/0000950103-26-009441.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950103-26-009441 | | 2026-05-13 | 16:22 ET | [8-K](/filings/0000950103-26-007158.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950103-26-007158 | | 2026-05-13 | 16:20 ET | [10-Q](/filings/0001356090-26-000017.md) | Quarterly report, period 2026-03-31 | 0001356090-26-000017 | | 2026-04-30 | 16:06 ET | [DEF 14A](/filings/0001140361-26-018214.md) | Proxy statement, period 2026-06-18 | 0001140361-26-018214 | | 2026-03-31 | 16:01 ET | [SCHEDULE 13D/A](/filings/0001213900-26-037403.md) | Ownership report, active investor, amended | 0001213900-26-037403 | | 2026-03-25 | 16:54 ET | [10-K](/filings/0001356090-26-000009.md) | Annual report, period 2025-12-31 | 0001356090-26-000009 | | 2026-03-25 | 16:52 ET | [8-K](/filings/0000950103-26-004648.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950103-26-004648 | | 2025-11-21 | 20:23 ET | [SCHEDULE 13D/A](/filings/0001213900-25-113780.md) | Ownership report, active investor, amended | 0001213900-25-113780 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001356090-26-000009.md), filed Mar 25, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/466363db-757a-4d75-8f5a-0ea6ed78d5b3) ## About the filer - CIK: 1356090 - Tickers: PGEN - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: VA - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.